NCT07110103 - Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 15, 2025

Primary Completion Date

March 31, 2027

Study Completion Date

June 30, 2028

Conditions

SCLCSCLC, Extensive Stage

Interventions

DRUG

golidocitinib with PD-1 inhibitors

"Dose escalation: 75/150mg golidocitinib with PD-1 inhibitors as maintenance treatment after 4 cycles of PD-1 inhibitors and chemotherapy.~Dose expansion: Selected dose (75mg or 150mg) of golidocitinib with PD-1 inhibitors as maintenance treatment after 4 cycles of PD-1 inhibitors and chemotherapy."

Trial Locations (2)

Unknown

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing

Xinqiao Hospital, Third Military Medical University, Chongqing